Your browser doesn't support javascript.
loading
Changes in cardiac cells due to ticagrelor and enoxaparin in a rat ischemia/reperfusion model.
Findik, Orhan; Baris, Ozgur; Yazir, Yusufhan; Yilmaz, Melda Yardimoglu; Rencber, Selenay Furat; Sarihan, Kübra Kavram; Kunt, Atike Tekeli.
Afiliación
  • Findik O; Health Sciences University, Derince Training and Research Hospital, Department of Cardiovascular Surgery - Kocaeli, Turkey.
  • Baris O; Kocaeli University, Faculty of Medicine, Department of Cardiovascular Surgery - Kocaeli, Turkey.
  • Yazir Y; Kocaeli University, Center for Stem Cell and Gene Therapies Research and Practice - Kocaeli, Turkey.
  • Yilmaz MY; Kocaeli University, Faculty of Medicine, Department of Histology and Embryology - Kocaeli, Turkey.
  • Rencber SF; Kocaeli University, Faculty of Medicine, Department of Histology and Embryology - Kocaeli, Turkey.
  • Sarihan KK; Kocaeli University, Faculty of Medicine, Department of Histology and Embryology - Kocaeli, Turkey.
  • Kunt AT; Kocaeli University, Faculty of Medicine, Department of Histology and Embryology - Kocaeli, Turkey.
Rev Assoc Med Bras (1992) ; 67(12): 1764-1770, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34909947
ABSTRACT

OBJECTIVE:

Studies on ischemia/reperfusion injury remain the focus of interest. Ticagrelor and enoxaparin, which are antiaggregant and anticoagulant drugs developed for use in many cardiovascular pathologies, are still included in many ischemia/reperfusion studies. Remarkably, their new protective effects, especially with regard to ticagrelor, continue to be reported in the current literature. The aim of this study was to evaluate the beneficial effects of ticagrelor and enoxaparin pretreatments on the rat heart with histological and immunohistochemical markers in an ischemia/reperfusion model.

METHODS:

Wistar-albino rats (weighing 350-400 g) were divided into four groups as follows Sham-Control (Group 1), Control-Saline+ischemia/reperfusion (Group 2), Ticagrelor+ischemia/reperfusion (Group 3), and Enoxaparin+ischemia/reperfusion (Group 4). The ischemia/reperfusion injury model was applied to Group 2, Group 3 and Group 4. Heart tissue sections were stained with hematoxylin and eosin for histological examinations. Caspase 3 immunostaining was evaluated to detect apoptosis in the heart tissue sections.

RESULTS:

Both pretreatments ameliorated the ischemic damage but especially tissue sections belonging to Group 3 were nearly similar to control levels. The results indicated that ischemia/reperfusion-induced myocardial damage was significantly increased in Group 2, whereas ticagrelor and enoxaparin pretreatments in Group 3 and Group 4 significantly decreased apoptotic scores and the histological appearance of the Group 3 close to the normal myocardium (p<0.001).

CONCLUSION:

As supported by histological findings in our study, ticagrelor and enoxaparin have protective properties for heart tissue in this ischemia/reperfusion injury model.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enoxaparina / Isquemia Tipo de estudio: Prognostic_studies Idioma: En Revista: Rev Assoc Med Bras (1992) Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enoxaparina / Isquemia Tipo de estudio: Prognostic_studies Idioma: En Revista: Rev Assoc Med Bras (1992) Año: 2021 Tipo del documento: Article